2. Search Result
Search Result
Results for "

Blm

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

3

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3239
    Belantamab mafodotin
    1 Publications Verification

    GSK2857916; Belantamab mafodotin-Blm

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity .
    Belantamab mafodotin
  • HY-12342
    ML216
    Maximum Cited Publications
    7 Publications Verification

    CID-49852229

    		 DNA/RNA Synthesis Cancer
    ML216 (CID-49852229) is a potent, selective and cell permeable inhibitor of the DNA unwinding activity of BLM helicase with IC50s of 2.98 μM and 0.97 μM for BLM full-length and BLM 636-1298, respectively. ML216 inhibits ssDNA-dependent ATPase activity of BLM with a Ki of 1.76 μM. Antitumor avtivity .
    ML216
  • HY-110185
    NSC 617145
    3 Publications Verification

    		 DNA/RNA Synthesis Cancer
    NSC 617145 is a selective werner syndrome helicase (WRN) helicase inhibitor with an IC50 value of 230 nM. NSC 617145 inhibits WRN ATPase, and induces double-strand breaks (DSB) and chromosomal abnormalities. NSC 617145 shows selective for WRN over BLM, FANCJ, ChlR1, RecQ, and UvrD helicases .
    NSC 617145
  • HY-111756
    BLM-IN-1
    1 Publications Verification

    		 Apoptosis Cancer
    BLM-IN-1 is an effective bloom syndrome protein (BLM) inhibitor. BLM-IN-1 has a high binding affinity with a KD valueof 1.81 μM. BLM-IN-1 has good inhibitory effect for BLM with an IC50 value of 0.95 μM. BLM-IN-1 can induce cell apoptosis. BLM-IN-1can be used for the research of DNA damage and cancer .
    BLM-IN-1
  • HY-128712
    NCGC00029283

    		DNA/RNA Synthesis Cancer
    NCGC00029283 is a werner syndrome helicase-nuclease (WRN) helicase inhibitor with IC50s of 2.3 μM, 12.5 μM, and 3.4 μM for WRN, BLM and FANCJ helicase, respectively .
    NCGC00029283
  • HY-151939
    BLM-IN-2

    		DNA/RNA Synthesis Apoptosis Cancer
    BLM-IN-2 is a Bloom's Syndrome Protein (BLM) inhibitor with an IC50 value of 0.8 μM. BLM-IN-2 effectively suppresses the proliferation, invasion, cell cycle arrest and apoptosis of CRC cells. BLM-IN-2 can be used for the reserarch of colorectal cancer (CRC) .
    BLM-IN-2
  • HY-178991
    WRN-IN-21

    		DNA/RNA Synthesis Cancer
    WRN-IN-21 (Compound 11b) is a WRN helicase inhibitor with pIC50 values for WRN and BLM helicases of 3.6 and 5.4 respectively. WRN-IN-21 can be used for the study of MSI-related cancers .
    WRN-IN-21
  • HY-176194
    Antifibrotic agent 1

    		Collagen c-Fms PDGFR Src Inflammation/Immunology
    Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model .
    Antifibrotic agent 1
  • HY-175033
    BRD4-IN-11

    		Epigenetic Reader Domain Phosphatase c-Myc Apoptosis Inflammation/Immunology
    BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis .
    BRD4-IN-11
  • HY-RS01520
    BLM Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    BLM Human Pre-designed siRNA Set A contains three designed siRNAs for BLM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BLM Human Pre-designed siRNA Set A
    BLM Human Pre-designed siRNA Set A
  • HY-RS16604
    Blm Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Blm Mouse Pre-designed siRNA Set A contains three designed siRNAs for Blm gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Blm Mouse Pre-designed siRNA Set A
    Blm Mouse Pre-designed siRNA Set A
  • HY-173483
    ATX inhibitor 26

    		Phosphodiesterase (PDE) ERK JNK p38 MAPK Inflammation/Immunology
    ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. ATX inhibitor 26 inhibits cell migration and collagen gel contraction. ATX inhibitor 26 has significant anti-fibrotic effects, reducing collagen deposition in a Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis model .
    ATX inhibitor 26
  • HY-175277
    PIM1-IN-8

    		Pim NF-κB Interleukin Related Inflammation/Immunology
    PIM1-IN-8 is a PIM1/p65 pathway inhibitor. PIM1-IN-8 suppresses the expression of α-SMA and collagen I in activated fibroblasts and blocks TGF-β induced migration. PIM1-IN-8 alleviates pulmonary fibrosis in a Bleomycin (BLM) (HY-17565A)-induced pulmonary fibrosis mice model. PIM1-IN-8 can be used for the study of idiopathic pulmonary fibrosis (IPF) .
    PIM1-IN-8
  • HY-RS23038
    Blm Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Blm Rat Pre-designed siRNA Set A contains three designed siRNAs for Blm gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Blm Rat Pre-designed siRNA Set A
    Blm Rat Pre-designed siRNA Set A
  • HY-181850
    Telomeric G4s ligand 2

    		G-quadruplex DNA/RNA Synthesis Cyclic GMP-AMP Synthase STING Autophagy Cancer
    Telomeric G4s ligand 2 is an orally active, selective ligand of telomeric G-quadruplex (G4), with an IC50 of 0.4 μM. Telomeric G4s ligand 2 binds to dimeric telomeric G4, inhibits the activities of DHX36 and BLM helicases. Telomeric G4s ligand 2 activates cGAS-STING and TERRA-ZBP1 pathways, inducing autophagy and G2/M cell cycle arrest, and exhibits antiproliferative effects across cancer cell lines. Telomeric G4s ligand 2 can be used for the study of colorectal cancer .
    Telomeric G4s ligand 2
  • HY-182634
    NCGC00063279

    		DNA/RNA Synthesis Phosphatase Cancer
    NCGC00063279 is a reversible Werner Syndrome Helicase-Nuclease (WRN) helicase inhibitor with modest selectivity over BLM and FANCJ helicases, and does not inhibit WRN exonuclease activity at active concentrations. NCGC00063279 inhibits Hematopoietic Protein Tyrosine Phosphatase (HePTP) and reduces proliferation of cancer cells. NCGC00063279 can be used for the research of osteosarcoma .
    NCGC00063279
  • HY-179645
    Phosphodiesterase-IN-5

    		Phosphodiesterase (PDE) PKA Interleukin Related TNF Receptor Collagen Inflammation/Immunology
    Phosphodiesterase-IN-5 is a potent, orally active and selective phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 6.2 nM. Phosphodiesterase-IN-5 shows >1612-fold selectivity over other PDEs. Phosphodiesterase-IN-5 exhibits potent antifibrotic efficacy in a Bleomycin (BLM) (HY-108345)-induced murine model of pulmonary fibrosis (PF) by blocking myofibroblast differentiation via the cAMP/PKA/CREB signaling pathway. Phosphodiesterase-IN-5 can be used for the research of PF .
    Phosphodiesterase-IN-5
  • HY-183610
    WRN-IN-26

    		DNA/RNA Synthesis PAK Cancer
    WRN-IN-26 is an orally active Werner syndrome helicase (WRN) inhibitor with a human Ki value of 58.7 μM and an IC50 value of 0.026 μM. WRN-IN-26 selectively targets the cysteine residues of WRN. WRN-IN-26 induces the expression of p21 protein in MSI-H tumor cells. WRN-IN-26 inhibits the growth of MSI-H tumor cells and exhibits potent in vivo efficacy in MSI-H xenograft tumor models. WRN-IN-26 can be used for the research of microsatellite instability-high (MSI-H) cancers .
    WRN-IN-26

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: